Skip to main content

#Avian #flu #risk still ‘low’ after first #US #patient dies from #H5N1 virus: #WHO

7 January 2025 

A day after the United States reported its first human death from avian flu, the UN World Health Organization (WHO) insisted on Tuesday that the risk to the wider population remains “low”. 

WHO spokesperson Dr. Margaret Harris told reporters in Geneva that the H5N1 virus causing the disease is “not circulating in humans but jumping into humans” who are exposed to poultry or dairy cattle. “We’re not seeing sustained circulation,” she insisted.


Underlying conditions

The man who died of the disease in Louisiana was over 65 and reportedly had underlying medical conditions, Dr. Harris said. 

According to the health authorities, he had been exposed to chickens and wild birds. Several dozen people in the US have contracted avian influenza – commonly referred to as bird flu – during the current outbreak, mainly farmworkers in close contact with poultry flocks and cattle herds.

Dr. Harris stressed that WHO’s assessment of the risk to the general population “is still low and remains set”. The main concern is for people who work in animal industries because they need to be better protected from infection.

The WHO spokesperson added that the United States was continuing to carry out “a lot of surveillance” in the human and animal population, “in the methods we use for farming, for our food production…all those things need to be combined because indeed it always does pose a risk”.


China respiratory virus is not new

Meanwhile, a respiratory virus gaining ground in China, known as the human metapneumovirus, or hMPV, has been sparking media attention in recent weeks, but it does not represent a new or major threat, Dr. Harris insisted.

The UN health agency spokesperson said that such infections are on the rise in China “as expected during winter”, with seasonal influenza being “by far the most common among them”, as reported by the Chinese Center for Disease Control and Prevention.

“China’s reported levels of respiratory infections are within the usual range for the winter season,” Dr. Harris explained. “Authorities report that hospital utilization is currently lower than this time last year, and there have been no emergency declarations or responses triggered,” she added.

As for hMPV, it was first identified in 2001 and “has been in the human population for a long time”, Dr. Harris clarified. 


‘Very, very low’ risk

She added that it is a common virus that circulates in winter and spring and usually “causes respiratory symptoms similar to the common cold”. 

Like any of the hundreds of common cold viruses known to exist, it can lead to more serious disease in patients with low immunity, particularly but not limited to newborns and the elderly.

Asked about hMPV’s mortality rate, Dr. Harris described it as “very, very low”. It is not a pathogen that normally leads to deaths in humans, save for the most vulnerable, she concluded, recommending “simple” prevention measures, such as wearing a mask, improving ventilation of closed spaces and handwashing.

Source: United Nations, https://news.un.org/en/story/2025/01/1158776

_____

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...